PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
MacroGenics, Inc. (MGNX)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS5560991094
CUSIP556099109
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$212.00M
EPS (TTM)-$2.23
PEG Ratio0.01
Total Revenue (TTM)$41.02M
Gross Profit (TTM)$30.28M
EBITDA (TTM)-$191.24M
Year Range$3.14 - $21.88
Target Price$7.25
Short %12.13%
Short Ratio5.69

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


MacroGenics, Inc.

Popular comparisons: MGNX vs. TRIP, MGNX vs. IR, MGNX vs. BMY, MGNX vs. OXLC, MGNX vs. SPLG

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in MacroGenics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-80.00%-60.00%-40.00%-20.00%0.00%20.00%AprilMayJuneJulyAugustSeptember
-80.60%
7.41%
MGNX (MacroGenics, Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

MacroGenics, Inc. had a return of -64.86% year-to-date (YTD) and -34.87% in the last 12 months. Over the past 10 years, MacroGenics, Inc. had an annualized return of -17.35%, while the S&P 500 had an annualized return of 10.67%, indicating that MacroGenics, Inc. did not perform as well as the benchmark.


PeriodReturnBenchmark
Year-To-Date-64.86%15.38%
1 month-7.14%5.03%
6 months-83.52%6.71%
1 year-34.87%23.24%
5 years (annualized)-24.03%13.10%
10 years (annualized)-17.35%10.67%

Monthly Returns

The table below presents the monthly returns of MGNX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202448.65%25.45%-17.95%0.41%-72.33%3.91%-11.53%-6.65%-64.86%
2023-14.01%5.55%17.73%-3.91%-32.22%14.56%-10.84%-2.31%-0.00%12.02%57.28%17.17%43.37%
2022-23.05%-24.29%-5.78%-18.84%-51.47%-14.99%6.10%26.84%-12.85%47.98%25.59%4.35%-58.19%
2021-10.59%22.36%27.35%1.60%-0.53%-16.56%-7.07%-5.41%-11.31%-6.73%-9.88%-8.81%-29.79%
2020-14.98%-5.19%-33.64%23.71%167.22%45.11%-9.03%13.94%-12.96%-22.95%18.86%-0.91%110.11%
2019-7.64%70.50%-10.10%-6.73%9.36%-7.47%-15.20%-0.35%-11.02%-33.39%11.41%14.89%-14.33%
201818.79%11.17%0.28%-8.35%-1.43%-9.15%0.00%5.91%-1.97%-23.23%4.56%-26.21%-33.16%
2017-9.64%14.46%-12.02%16.18%-17.86%-1.35%-5.65%14.47%-2.27%7.09%-2.37%-1.66%-7.05%
2016-35.00%-20.62%17.33%9.65%24.32%5.59%13.34%-2.55%0.34%-20.80%9.46%-21.17%-34.00%
2015-9.84%9.33%-9.26%-8.80%13.07%17.37%-0.97%-29.92%-18.71%45.05%11.30%-10.44%-11.69%
201445.13%-12.08%-20.49%-28.35%-6.42%16.45%-6.58%5.22%-2.15%1.87%32.74%24.10%27.85%
20137.80%-1.74%3.63%9.76%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of MGNX is 43, suggesting that the investment has average results relative to other stocks in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.


The Risk-Adjusted Performance Rank of MGNX is 4343
MGNX (MacroGenics, Inc.)
The Sharpe Ratio Rank of MGNX is 3434Sharpe Ratio Rank
The Sortino Ratio Rank of MGNX is 5454Sortino Ratio Rank
The Omega Ratio Rank of MGNX is 6363Omega Ratio Rank
The Calmar Ratio Rank of MGNX is 2727Calmar Ratio Rank
The Martin Ratio Rank of MGNX is 3535Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for MacroGenics, Inc. (MGNX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


MGNX
Sharpe ratio
The chart of Sharpe ratio for MGNX, currently valued at -0.29, compared to the broader market-4.00-2.000.002.00-0.29
Sortino ratio
The chart of Sortino ratio for MGNX, currently valued at 0.73, compared to the broader market-6.00-4.00-2.000.002.004.000.73
Omega ratio
The chart of Omega ratio for MGNX, currently valued at 1.15, compared to the broader market0.501.001.501.15
Calmar ratio
The chart of Calmar ratio for MGNX, currently valued at -0.36, compared to the broader market0.001.002.003.004.005.00-0.36
Martin ratio
The chart of Martin ratio for MGNX, currently valued at -0.71, compared to the broader market-10.00-5.000.005.0010.0015.0020.00-0.71
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 1.78, compared to the broader market-4.00-2.000.002.001.78
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 2.44, compared to the broader market-6.00-4.00-2.000.002.004.002.44
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.32, compared to the broader market0.501.001.501.32
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.58, compared to the broader market0.001.002.003.004.005.001.58
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 8.48, compared to the broader market-10.00-5.000.005.0010.0015.0020.008.48

Sharpe Ratio

The current MacroGenics, Inc. Sharpe ratio is -0.29. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of MacroGenics, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00AprilMayJuneJulyAugustSeptember
-0.29
1.78
MGNX (MacroGenics, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


MacroGenics, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%AprilMayJuneJulyAugustSeptember
-91.59%
-2.89%
MGNX (MacroGenics, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the MacroGenics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the MacroGenics, Inc. was 94.40%, occurring on Jun 16, 2022. The portfolio has not yet recovered.

The current MacroGenics, Inc. drawdown is 91.59%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-94.4%Jan 21, 20142118Jun 16, 2022
-23.38%Nov 14, 20136Nov 21, 201327Jan 2, 201433
-7.46%Oct 25, 201311Nov 8, 20133Nov 13, 201314
-4.18%Oct 14, 20132Oct 15, 20135Oct 22, 20137
-3.86%Oct 23, 20131Oct 23, 20131Oct 24, 20132

Volatility

Volatility Chart

The current MacroGenics, Inc. volatility is 20.40%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%50.00%100.00%150.00%AprilMayJuneJulyAugustSeptember
20.40%
4.56%
MGNX (MacroGenics, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of MacroGenics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for MacroGenics, Inc..


Loading data...

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items